Ptcbio.com

Site Inspections

Overview & More informations

PTC Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases. The company's lead product, Translarna (ataluren), is approved in the United States and Europe for the treatment of nonsense mutation dystrophinopathies, a rare genetic disease that affects muscle function. PTC Therapeutics is also developing several other product candidates for the treatment of rare diseases, including PTC518, a potential treatment for spinal muscular atrophy, and PTC701, a potential treatment for cystic fibrosis. The company has a strong track record of success in developing and commercializing innovative therapies for rare diseases, and is well-positioned for continued growth in the future.

PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, New Jersey. The company has a global presence, with operations in the United States, Europe, and Asia. PTC Therapeutics is a publicly traded company, and its stock is traded on the Nasdaq Global Select Market under the symbol PTCT.

PTC Therapeutics is a leader in the field of rare disease research and development. The company's mission is to improve the lives of patients with rare diseases by developing and commercializing innovative therapies. PTC Therapeutics has a strong commitment to patient care, and the company works closely with patient advocacy groups to ensure that patients have access to the latest treatments.

PTC Therapeutics is a valuable resource for patients with rare diseases. The company's website provides information about the company's products, clinical trials, and patient support programs. PTC Therapeutics also has a strong social media presence, and the company uses these channels to connect with patients and provide them with up-to-date information about the company's products and services.

Domains Expiration Date Updated